Home

This is a temporarily open system that will be closed on February 25, 2025, and all review processes will follow the previous review standards (https://www.eurekaselect.com/journal/70/ifa), during the peer review process, strict adherence to peer review standards will be followed, and once accepted, the manuscript will be submitted to KeAi Publishing House for publication (The journal homepage is under construction).

The Current Proteomics manuscript submission system is currently being upgraded. The new system will be Elsevier's EM system, which is scheduled to be officially launched on February 23, 2025. Until then, the OJS submission system will be used temporarily, and manuscripts submitted through this system will undergo double-blind peer review, just like formally submitted manuscripts.

It should be noted that manuscripts submitted to this system will be published in an open access manner.

This is a temporary submission system that has been put into use. If you have any questions about submission, please contact the editorial office: cp@techscipub.com

Current Proteomics is one of the pharmaceutical series journals under KeAi Publishing, which is responsible for our journal's publication. Our journal will use the Elsevier's Editorial Manager (EM) submission system, but during the set up of the EM system, the Open Journal Systems (OJS) system is temporarily being used for submissions.

Elsevier publishes over 2,500 digital journals, including The Lancet and Cell, as well as 39,000 e-books and many iconic reference works. KeAi Publishing currently has more than 200 journals, and it was jointly established by two world's leading STM publishers—China Science Publishing & Media and Elsevier. It is a unique joint venture in the international publishing industry. KeAi Publishing, based in Beijing, publishes first-class research results that benefit global society. The official website of KeAi Publishing is https://www.keaipublishing.com/en/.

About the submission system: This is a temporary submission system. During the set up of the new system, Current Proteomics will use the OJS system as an interim solution. Once Elsevier successfully builds the EM system for our journal, all manuscripts submitted during this period will be transferred to Elsevier's EM system and published by KeAi Publishing.